1.23
-0.03(-2.38%)
Currency In USD
| Previous Close | 1.26 |
| Open | 1.24 |
| Day High | 1.29 |
| Day Low | 1.2 |
| 52-Week High | 13.24 |
| 52-Week Low | 1.01 |
| Volume | 737,466 |
| Average Volume | 906,926 |
| Market Cap | 88.33M |
| PE | -0.53 |
| EPS | -2.33 |
| Moving Average 50 Days | 1.58 |
| Moving Average 200 Days | 2.75 |
| Change | -0.03 |
If you invested $1000 in Zentalis Pharmaceuticals, Inc. (ZNTL) since IPO date, it would be worth $53.02 as of May 10, 2025 at a share price of $1.23. Whereas If you bought $1000 worth of Zentalis Pharmaceuticals, Inc. (ZNTL) shares 3 years ago, it would be worth $61.29 as of May 10, 2025 at a share price of $1.23.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC
GlobeNewswire Inc.
Apr 28, 2025 12:00 PM GMT
Phase 2 registration-intent trial enrolling Part 2a dose confirmation arms Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback SAN DIEGO, April 28, 2025 (GLOBE
Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting
GlobeNewswire Inc.
Apr 23, 2025 8:05 PM GMT
SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and o
Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025
GlobeNewswire Inc.
Mar 25, 2025 8:40 PM GMT
One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in patients with high-grade serous ovarian cancer (HGSOC) Three additional posters highlighting the potential for